Histologic remission and mucosal healing in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

Rish K. Pai  1     James Canavan  2     Jay Tuttle  3     Michael Durante  3     Vipin Arora  3     Catherine Milch  3     Noam Harpaz  4     Geert D’Haens     Bruce E. Sands     William Sandborn    
1 Mayo Clinic,Phoenix,United States
2 Formerly of Eli Lilly and Company,Indianapolis,United States
3 Eli Lilly and Company,Indianapolis,United States
4 The Mount Sinai Medical Center,New Yor

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing